STOCKHOLM, March 9, 2017 /PRNewswire/ -- As SCA communicated in December 2016, the Group has
1)Excluding items affecting comparability
NB: This information is information that SCA is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 20:00 CET on March 9, 2017.
Karl Stoltz, Media Relations Manager, +46-8-788-51-55
For additional information please contact:Johan Karlsson, Vice President Investor Relations, 46 (0)8 788 51 30Karl Stoltz, Media Relations Manager, 46 (0)8 788 51 55
This information was brought to you by Cision http://news.cision.comhttp://news.cision.com/sca/r/bsn-medical-s-sales-and-ebitda-for-2016,c2209205
The following files are available for download:
http://mb.cision.com/Main/600/2209205/640475.pdf BSN medicalâs sales and EBITDA for 2016
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bsn-medicals-sales-and-ebitda-for-2016-300421406.html
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All